Plasma Cell Homeostasis: the Effects of Chronic Antigen Stimulation and Inflammation

Total Page:16

File Type:pdf, Size:1020Kb

Plasma Cell Homeostasis: the Effects of Chronic Antigen Stimulation and Inflammation Plasma Cell Homeostasis: The Effects of Chronic Antigen Stimulation and Inflammation This information is current as Tom Slocombe, Sheila Brown, Katherine Miles, Mohini of September 26, 2021. Gray, Tom A. Barr and David Gray J Immunol published online 9 August 2013 http://www.jimmunol.org/content/early/2013/08/09/jimmun ol.1301163 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2013/08/12/jimmunol.130116 Material 3.DC1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 26, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published August 9, 2013, doi:10.4049/jimmunol.1301163 The Journal of Immunology Plasma Cell Homeostasis: The Effects of Chronic Antigen Stimulation and Inflammation Tom Slocombe,*,† Sheila Brown,*,† Katherine Miles,‡ Mohini Gray,‡ Tom A. Barr,*,†,1 and David Gray*,† Long-lived plasma cells (LLPCs) that maintain humoral immunity to previously encountered Ags occupy a compartment in the bone marrow (BM). The rules and mechanisms by which cells enter (and leave) this compartment are poorly understood. We looked at what happens to the LLPC compartment and to plasma cell lifespan in general, in situations in which Ag stimulation and/or inflammation persist. We find that chronic Ag supply causes the generation of short-lived plasma cells in the local lymphoid organ, at the expense of any LLPC production. Furthermore, we find that inflammation caused by infection (mediated via TNF-a)causesa dramatic mobilization of LLPCs from the BM, with a concomitant reduction in circulating Ab levels against previously immunized Ags. These data are discussed in the context of the capacity of the BM LLPC compartment and competition for entry to it. The Downloaded from Journal of Immunology, 2013, 191: 000–000. ollowing vaccination or infection, Ab levels persist for mablasts emerge at a time when the extrafollicular PC response has many years (1, 2), and this humoral immunity is key to waned. Therefore, the GC-derived plasmablasts do not settle in the F providing protection from reinfection. The main source of red pulp, but rather respond to CXCL12 (7) in the circulation and these Abs is long-lived plasma cells (LLPCs) that are generated in migrate to the BM (10–12). Under other conditions, such as infec- http://www.jimmunol.org/ the secondary lymphoid organs but reside primarily in the bone tion, the local CXCL12 production may be increased and prolonged marrow (BM) (3–5). However, many short-lived PCs (SLPCs) are and so GC-derived plasmablasts may remain in the spleen. The GC- also generated during the early phases of T-dependent immune derived plasmablasts are also capable of migrating to sites of in- responses. These two types of plasma cells (PCs) are the result of flammation guided by CXCR3 (attracted by CXCL9, CXCL10, and two distinct waves of differentiation; a first wave occurs following CXCL11) (13). initial interactions between activated, Ag-specific CD4 T and B cells PCs are inherently short-lived, surviving for just 2–3 d unsupported, at the border of the T zone (6). Some B cells become plasmablasts and yet their lifespan can be extended, almost indefinitely, by the andupregulateCXCR4,migratingtotheredpulpinresponseto provision of survival factors (14). These include soluble factors (such CXCL12 gradients (7). Here they form the extrafollicular foci of as a proliferation-inducing ligand [APRIL], BAFF, IL-6, TNF-a,and by guest on September 26, 2021 PCs (8), which no longer divide and have lost many B cell–associated CXCL12) and membrane receptors (such as CD44, LFA-1:ICAM-1, markers (e.g., MHC class II, B220, CD19, CD20). Although mas- VLA-4:VCAM-1) (14) that act synergistically to provide a survival sive in scale, this extrafollicular PC response is transient, because niche. BCMA ligands (APRIL and BAFF) seem especially impor- most of these cells die within a few days (9). Several days later, a tant for long-term survival in the BM (15, 16), as is CD93 (17) and second wave of plasmablasts emerges from the germinal center possibly CD28 (18, 19). These factors are enriched only in the BM (GC) reaction. These cells are generally class switched and secrete under homeostatic conditions, provided by a complex cellular niche: high-affinity Ab molecules containing V-region mutations. If the eosinophils (20), megakaryocytes (21), and myeloid cells (22) pos- GC were initiated by classical immunization, generally the plas- sibly clustering around VCAM-1+ stromal cells (attracted by CXCL12) where they provide signals to plasmablasts and early PCs that also migrate toward CXCL12. Supported by a survival niche, *Institute of Immunology and Infection Research, School of Biological Sciences, PCs endure at this site for many months or even years without di- University of Edinburgh, Edinburgh EH9 3JT, United Kingdom; †Centre for Immu- vision or replenishment from the peripheral B cell pool. Survival nity, Infection, and Evolution, School of Biological Sciences, University of Edinburgh, niches are also induced in other organs during inflammation, al- Edinburgh EH9 3JT, United Kingdom; and ‡The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, EH16 4TJ, United Kingdom though their characterization is incomplete (23). In the secondary + 2 1Current address: Institute of Infection, Immunity, and Inflammation, University of lymphoid organs, IL-6–secreting CD11c CD8a dendritic cells Glasgow, Glasgow, U.K. support plasmablast survival, whereas APRIL- and BAFF-secreting Received for publication May 1, 2013. Accepted for publication July 8, 2013. populations support PC survival in the red pulp and medullary cords This work was supported by a Medical Research Council studentship (to T.S.) and by (8, 24). These populations are expanded during inflammation, a Programme Grant from the Wellcome Trust (to D.G.). allowing for the temporary survival of large numbers of plasmablasts Address correspondence and reprint requests to Prof. David Gray, Institute of Immu- and PCs. However, under steady-state conditions, relatively few nology and Infection Research, University of Edinburgh, Ashworth Laboratories, LLPCs are supported in the secondary lymphoid organs (9). King’s Buildings, West Mains Road, Edinburgh EH9 3JT, U.K. E-mail address: [email protected] In this study, we wished to determine how chronic Ag supply and/ The online version of this article contains supplemental material. or inflammation affected the survival and turnover of PCs in local Abbreviations used in this article: APRIL, a proliferation-inducing ligand; BM, bone lymphoid tissues and in the LLPC compartment of the BM. Both marrow; GC, germinal center; KLH, keyhole limpet hemocyanin; LLPC, long-lived myeloid and B lymphocyte development are known to be influ- plasma cell; NP, nitrophenyl; PC, plasma cell; SLPC, short-lived plasma cell; TT, enced by systemic inflammatory mediators (25), and mobilization tetanus toxoid. of BM PCs upon Ag rechallenge was noted previously (26). This Copyright Ó 2013 by The American Association of Immunologists, Inc. 0022-1767/13/$16.00 suggests that inflammatory signals might also affect the LLPC www.jimmunol.org/cgi/doi/10.4049/jimmunol.1301163 2 INFLAMMATION AND PLASMA CELL HOMEOSTASIS compartment. Therefore, we investigated how competing immune A total of 600 ml medium, with or without recombinant mouse chemokines responses under inflammatory or noninflammatory conditions affect at 400 nM (CXCL9 or CXCL12; R&D Systems), was added to the lower pre-existing BM PC populations and the laying down of new LLPCs well, and 100 ml spleen cells was added to the upper well. Cells were allowed to migrate for 3 h at 37˚C. The contents of the lower well were harvested and in the BM. Our findings suggest that, in addition to Ag chronicity and resuspended in 5% FCS IMDM before culturing on ELISPOT plates over- inflammation causing the generation of SLPCs at the expense of night. For assay of chemokines in spleen or BM ex vivo, cells were mashed LLPCs, inflammation (e.g., TNF-a) caused a general mobilization of or flushed into PBS and spun down, and supernatants were collected for existing LLPCs from the BM that may be important to facilitate entry assay. of newly formed LLPCs into the compartment. ELISPOT Ninety-six–well multiscreen plates (Millipore) were treated with 15% eth- Materials and Methods anol for 1 min, washed in PBS, and coated with NP-BSA or FITC-OVA, at Mice 10 mg/ml, in carbonate/bicarbonate buffer (Sigma) overnight at 4˚C. Plates were washed (PBS), blocked with 10% FCS-PBS for 2 h, and washed. Du- C57BL/6 mice, K/BxN mice (27), MyD88-deficient mice (28), TLR4- plicate 5-fold cell dilutions were incubated overnight at 37˚C before washing deficient mice (29), and TRIF-deficient mice (30) were bred and main- with PBS and PBS-0.1% Tween (nine washes). Finally, anti–IgG–alkaline tained in specific pathogen–free conditions at the School of Biological phosphatase (Southern Biotech) was added to each well for 4 h at room Sciences Animal Facility at the University of Edinburgh. Mice were aged temperature. Plates were developed using SIGMAFAST (Sigma), and spots 6–10 wk at the start of experiments, unless otherwise stated. The MyD88-, were scored under a microscope.
Recommended publications
  • IFM Innate Immunity Infographic
    UNDERSTANDING INNATE IMMUNITY INTRODUCTION The immune system is comprised of two arms that work together to protect the body – the innate and adaptive immune systems. INNATE ADAPTIVE γδ T Cell Dendritic B Cell Cell Macrophage Antibodies Natural Killer Lymphocites Neutrophil T Cell CD4+ CD8+ T Cell T Cell TIME 6 hours 12 hours 1 week INNATE IMMUNITY ADAPTIVE IMMUNITY Innate immunity is the body’s first The adaptive, or acquired, immune line of immunological response system is activated when the innate and reacts quickly to anything that immune system is not able to fully should not be present. address a threat, but responses are slow, taking up to a week to fully respond. Pathogen evades the innate Dendritic immune system T Cell Cell Through antigen Pathogen presentation, the dendritic cell informs T cells of the pathogen, which informs Macrophage B cells B Cell B cells create antibodies against the pathogen Macrophages engulf and destroy Antibodies label invading pathogens pathogens for destruction Scientists estimate innate immunity comprises approximately: The adaptive immune system develops of the immune memory of pathogen exposures, so that 80% system B and T cells can respond quickly to eliminate repeat invaders. IMMUNE SYSTEM AND DISEASE If the immune system consistently under-responds or over-responds, serious diseases can result. CANCER INFLAMMATION Innate system is TOO ACTIVE Innate system NOT ACTIVE ENOUGH Cancers grow and spread when tumor Certain diseases trigger the innate cells evade detection by the immune immune system to unnecessarily system. The innate immune system is respond and cause excessive inflammation. responsible for detecting cancer cells and This type of chronic inflammation is signaling to the adaptive immune system associated with autoimmune and for the destruction of the cancer cells.
    [Show full text]
  • Adoptive Cell Therapy Using Engineered Natural Killer Cells
    Bone Marrow Transplantation (2019) 54:785–788 https://doi.org/10.1038/s41409-019-0601-6 REVIEW ARTICLE Adoptive cell therapy using engineered natural killer cells Katayoun Rezvani1 © The Author(s), under exclusive licence to Springer Nature Limited 2019 Abstract The generation of autologous T cells expressing a chimeric antigen receptor (CAR) have revolutionized the field of adoptive cellular therapy. CAR-T cells directed against CD19 have resulted in remarkable clinical responses in patients affected by B-lymphoid malignancies. However, the production of allogeneic CAR-T cells products remains expensive and clinically challenging. Moreover, the toxicity profile of CAR T-cells means that currently these life-saving treatments are only delivered in specialized centers. Therefore, efforts are underway to develop reliable off-the-shelf cellular products with acceptable safety profiles for the treatment of patients with cancer. Natural killer (NK) cells are innate effector lymphocytes with potent antitumor activity. The availability of NK cells from multiple sources and their proven safety profile in the allogeneic setting positions them as attractive contenders for cancer immunotherapy. In this review, we discuss advantages and potential drawbacks of using NK cells as a novel cellular therapy against hematologic malignancies, as well as strategies 1234567890();,: 1234567890();,: to further enhance their effector function. Introduction need for inpatient care may ultimately be economically unviable for many health care systems; (iii) the longer time Adoptive cell therapy has become a powerful treatment that is required to generate CAR T-cells may result in modality for advanced cancers refractory to conventional unavoidable delays in therapy, especially for patients with therapy.
    [Show full text]
  • Targeting Dendritic Cells with Antigen-Delivering Antibodies for Amelioration of Autoimmunity in Animal Models of Multiple Sclerosis and Other Autoimmune Diseases
    antibodies Review Targeting Dendritic Cells with Antigen-Delivering Antibodies for Amelioration of Autoimmunity in Animal Models of Multiple Sclerosis and Other Autoimmune Diseases Courtney A. Iberg and Daniel Hawiger * Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, Doisy Research Center, 1205 Carr Lane, St. Louis, MO 63104, USA; [email protected] * Correspondence: [email protected] Received: 31 March 2020; Accepted: 30 April 2020; Published: 15 June 2020 Abstract: The specific targeting of dendritic cells (DCs) using antigen-delivering antibodies has been established to be a highly efficient protocol for the induction of tolerance and protection from autoimmune processes in experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS), as well as in some other animal disease models. As the specific mechanisms of such induced tolerance are being investigated, the newly gained insights may also possibly help to design effective treatments for patients. Here we review approaches applied for the amelioration of autoimmunity in animal models based on antibody-mediated targeting of self-antigens to DCs. Further, we discuss relevant mechanisms of immunological tolerance that underlie such approaches, and we also offer some future perspectives for the application of similar methods in certain related disease settings such as transplantation. Keywords: dendritic cells; tolerance; antigen targeting; chimeric antibodies; autoimmunity; multiple sclerosis; diabetes 1. Introduction Over one hundred years ago, Paul Ehrlich coined the term “horror autotoxicus” to define an immune attack against an organism’s healthy tissues [1]. Since then, our knowledge of the complex mechanisms of the immune system as well as our understanding of the pathogenesis of specific autoimmune diseases have grown tremendously.
    [Show full text]
  • Eosinophil Response Against Classical and Emerging
    REVIEWS Eosinophil Response Against Classical and Emerging Respiratory Viruses: COVID-19 Rodrigo-Muñoz JM1,2, Sastre B1,2, Cañas JA1,2, Gil-Martínez M1, Redondo N1, del Pozo V1,2 1Immunology Department, Instituto de Investigación Sanitaria (IIS) Fundación Jiménez Díaz, Madrid, Spain 2CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain J Investig Allergol Clin Immunol 2021; Vol. 31(2): 94-107 doi: 10.18176/jiaci.0624 Abstract Eosinophils were discovered more than 140 years ago. These polymorphonuclear leukocytes have a very active metabolism and contain numerous intracellular secretory granules that enable multiple effects on both health and disease status. Classically, eosinophils have been considered important immune cells in the pathogenesis of inflammatory processes (eg, parasitic helminth infections) and allergic or pulmonary diseases (eg, asthma) and are always associated with a type 2 immune response. Furthermore, in recent years, eosinophils have been linked to the immune response by conferring host protection against fungi, bacteria, and viruses, which they recognize through several molecules, such as toll-like receptors and the retinoic acid–inducible gene 1–like receptor. The immune protection provided by eosinophils is exerted through multiple mechanisms and properties. Eosinophils contain numerous cytoplasmatic granules that release cationic proteins, cytokines, chemokines, and other molecules, all of which contribute to their functioning. In addition to the competence of eosinophils as effector cells, their capabilities as antigen-presenting cells enable them to act in multiple situations, thus promoting diverse aspects of the immune response. This review summarizes various aspects of eosinophil biology, with emphasis on the mechanisms used and roles played by eosinophils in host defence against viral infections and response to vaccines.
    [Show full text]
  • Understanding the Immune System: How It Works
    Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them.
    [Show full text]
  • Antibody-Antigen Interaction (Anti-Nucleotide Antibody/Anti-Hapten Antibody) ROBERT J
    Proc. Nati. Acad. Sci. USA Vol. 77, No. 12, pp. 7410-7414, December 1980 Immunology Anti-AMP antibody precipitation of multiply adenylylated forms of glutamine synthetase from Escherichia coli: A model relating both concentration and density of antigenic sites with the antibody-antigen interaction (anti-nucleotide antibody/anti-hapten antibody) ROBERT J. HOHMAN*, SUE Goo RHEEt, AND EARL R. STADTMANtt tLaboratory of Biochemistry, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20205; and *Department of Microbiology, University of Maryland, College Park, Maryland 20742 Contributed by E. R. Stadtman, September 12, 1980 ABSTRACT Sheep antibodies directed against an AMP- ylylated forms of GS to determine the effects of the total con- bovine serum albumin conjugate exhibit highly specific binding centration of antigenic determinants, density of determinants toward AMP. These antibodies bind to the AMP moiety of ad- enylylated glutamine synthetase [-glutamate:ammonia ligase per antigen, and the topological distribution of antigenic de- (ADP-forming), EC 6.3.1.2] from Escherichia coli and to no other terminants, on the initial antibody-antigen binding, lattice antigenic determinant on the protein. E. coli glutamine syn- formation, and immunoprecipitation.§ Some of the experi- thetase can exist in variously modified (isomeric) forms that mental data were presented in an earlier preliminary com- differ with respect to the number (0-12) and the distribution of munication (3). identically adenylylated subunits [Ciardi, J. E., Cimino, F. & Stadtman, E. R. (1973) Biochemistry 12,432143301. Using this MATERIALS AND METHODS enzyme, together with the AMP-specific antibodies, we have investigated the effects of the total concentration, population Purification and Assay of GS.
    [Show full text]
  • Plasma Cells: Finding New Light at the End of B Cell Development Kathryn L
    © 2001 Nature Publishing Group http://immunol.nature.com REVIEW Plasma cells: finding new light at the end of B cell development Kathryn L. Calame Plasma cells are cellular factories devoted entire- Upon plasma cell differentiation, there is a marked increase in ly to the manufacture and export of a single prod- steady-state amounts of Ig heavy and light chain mRNA and, when 2 uct: soluble immunoglobulin (Ig). As the final required for IgM and IgA secretion, J chain mRNA . Whether the increase in Ig mRNA is due to increased transcription, increased mediators of a humoral response, plasma cells mRNA stability or, as seems likely, both mechanisms, remains con- play a critical role in adaptive immunity.Although troversial2. There is also an increase in secreted versus membrane intense effort has been devoted to studying the forms of heavy chain mRNA, as determined by differential use of poly(A) sites that may involve the availability of one component of regulation and requirements for early B cell the polyadenylation machinery, cleavage-stimulation factor Cst-643. development, little information has been avail- To accommodate translation and secretion of the abundant Ig able on plasma cells. However, more recent mRNAs, plasma cells have an increased cytoplasmic to nuclear ratio work—including studies on genetically altered and prominent amounts of rough endoplasmic reticulum and secreto- ry vacuoles. mice and data from microarray analyses—has Numerous B cell–specific surface proteins are down-regulated begun to identify the regulatory cascades that upon plasma cell differentiation, including major histocompatibility initiate and maintain the plasma cell phenotype. complex (MHC) class II, B220, CD19, CD21 and CD22.
    [Show full text]
  • REVIEW Multiple Myeloma: the Cells of Origin – a Two-Way Street
    Leukemia (1998) 12, 121–127 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 REVIEW Multiple myeloma: the cells of origin – A two-way street JR Berenson, RA Vescio and J Said West Los Angeles VA Medical Center, UCLA School of Medicine, Los Angeles, CA, USA Multiple myeloma results from an interplay between the mono- earlier precursor cells may be responsible for the proliferation clonal malignant plasma cells and supporting nonmalignant of the malignant population. The presence of a circulating cells in the bone marrow. Recent studies suggest that the final transforming event in this B cell disorder occurs at a late stage tumor component without obvious plasma cell morphology of B cell differentiation based on the characteristics of the also suggests that less mature lymphocytes may be part of the immunoglobulin genes expressed by the malignant clone as clone as well, which could explain the dissemination of the well as surface markers present on the tumor cells. Recently, disease throughout the bone marrow.4 In addition, evidence an increasing pathogenic role in this malignancy by the nonma- for tumor cells at even earlier stages of hematopoietic differen- lignant cells in the bone marrow has been suggested by several tiation came from studies showing the high rate of acute non- studies. Specific infection of these supporting cells by the lymphoblastic leukemia in these patients and the presence of recently identified Kaposi’s sarcoma-associated herpes virus 5,6 (KSHV) suggests a novel mechanism by which this nonmalig- non-lymphoid surface markers on malignant plasma cells. A nant population may lead to the development of this B cell variety of molecular biological techniques have subsequently malignancy and support its growth.
    [Show full text]
  • (COVID-19): PCR, Antigen, and Antibody Tests There Are Three Types of Tests Available for SARS-Cov-2, the Virus
    Coronavirus 2019 (COVID-19): PCR, Antigen, and Antibody Tests There are three types of tests available for SARS-CoV-2, the virus that causes COVID-19: polymerase chain reaction (PCR), antigen, and antibody (serology) testing. PCR and antigen tests detect whether a person is currently infected, and serology detects whether a person had an infection in the past. All positive and negative test results for SARS-CoV2 are reportable in the District of Columbia. This document provides information about each type of test. Topic PCR Test Antigen Test Antibody (Serology) Test Why is the test PCR tests look for pieces of Antigen tests look for pieces of Serology looks for antibodies1 against used? genetic material of SARS-CoV-2, proteins that make up the SARS- SARS-CoV-2, the virus that causes the virus that causes COVID-19, in CoV-2 virus, the virus that causes COVID-19, in the blood to determine if the nose, throat, or other areas in COVID-19, to determine if the person there was a past infection. the respiratory tract to determine if has an active (i.e., current) infection. the person has an active (i.e., current) infection. How is the test In most cases, a nasopharyngeal In most cases, a nasopharyngeal In most cases, a blood sample is taken performed? or nasal swab is taken by a nasal swab is taken by a healthcare and sent to a lab for testing. healthcare provider and tested; provider and tested. Most often the however, oral swabs and saliva test can be run while you wait, and can be used.
    [Show full text]
  • Restoring Natural Killer Cell Immunity Against Multiple Myeloma in the Era of New Drugs
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Institutional Research Information System University of Turin Restoring Natural Killer Cell immunity against Multiple Myeloma in the era of New Drugs Gianfranco Pittari1, Luca Vago2,3, Moreno Festuccia4,5, Chiara Bonini6,7, Deena Mudawi1, Luisa Giaccone4,5 and Benedetto Bruno4,5* 1 Department of Medical Oncology, National Center for Cancer Care and Research, HMC, Doha, Qatar, 2 Unit of Immunogenetics, Leukemia Genomics and Immunobiology, IRCCS San Raffaele Scientific Institute, Milano, Italy, 3 Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy, 4 Department of Oncology/Hematology, A.O.U. Città della Salute e della Scienza di Torino, Presidio Molinette, Torino, Italy, 5 Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy, 6 Experimental Hematology Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milano, Italy, 7 Vita-Salute San Raffaele University, Milano, Italy Transformed plasma cells in multiple myeloma (MM) are susceptible to natural killer (NK) cell-mediated killing via engagement of tumor ligands for NK activating receptors or “missing-self” recognition. Similar to other cancers, MM targets may elude NK cell immunosurveillance by reprogramming tumor microenvironment and editing cell surface antigen repertoire. Along disease continuum, these effects collectively result in a pro- gressive decline of NK cell immunity, a phenomenon increasingly recognized as a critical determinant of MM progression. In recent years, unprecedented efforts in drug devel- opment and experimental research have brought about emergence of novel therapeutic interventions with the potential to override MM-induced NK cell immunosuppression.
    [Show full text]
  • Vaccine Immunology Claire-Anne Siegrist
    2 Vaccine Immunology Claire-Anne Siegrist To generate vaccine-mediated protection is a complex chal- non–antigen-specifc responses possibly leading to allergy, lenge. Currently available vaccines have largely been devel- autoimmunity, or even premature death—are being raised. oped empirically, with little or no understanding of how they Certain “off-targets effects” of vaccines have also been recog- activate the immune system. Their early protective effcacy is nized and call for studies to quantify their impact and identify primarily conferred by the induction of antigen-specifc anti- the mechanisms at play. The objective of this chapter is to bodies (Box 2.1). However, there is more to antibody- extract from the complex and rapidly evolving feld of immu- mediated protection than the peak of vaccine-induced nology the main concepts that are useful to better address antibody titers. The quality of such antibodies (e.g., their these important questions. avidity, specifcity, or neutralizing capacity) has been identi- fed as a determining factor in effcacy. Long-term protection HOW DO VACCINES MEDIATE PROTECTION? requires the persistence of vaccine antibodies above protective thresholds and/or the maintenance of immune memory cells Vaccines protect by inducing effector mechanisms (cells or capable of rapid and effective reactivation with subsequent molecules) capable of rapidly controlling replicating patho- microbial exposure. The determinants of immune memory gens or inactivating their toxic components. Vaccine-induced induction, as well as the relative contribution of persisting immune effectors (Table 2.1) are essentially antibodies— antibodies and of immune memory to protection against spe- produced by B lymphocytes—capable of binding specifcally cifc diseases, are essential parameters of long-term vaccine to a toxin or a pathogen.2 Other potential effectors are cyto- effcacy.
    [Show full text]
  • Human Antigen-Specific Memory Natural Killer Cell Responses
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.09.374348; this version posted November 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Human antigen-specific memory natural killer cell responses develop 2 against HIV-1 and influenza virus and are dependent on MHC-E 3 restriction 4 5 6 Stephanie Jost1, Olivier Lucar1, Taylor Yoder1, Kyle Kroll1, Sho Sugawara1, Scott Smith1, Rhianna 7 Jones1, George Tweet1, Alexandra Werner1, Phillip J. Tomezsko2, Haley L. Dugan2†, Joshua 1 3 3 4 5 8 Ghofrani , Marcus Altfeld , Adam Grundhoff , Michaela Muller-Trutwin , Paul Goepfert , R. Keith 9 Reeves1,2 * 10 11 1Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard 12 Medical School, Boston, MA 02115, USA; 2Ragon Institute of Massachusetts General Hospital, 13 MIT, and Harvard, Cambridge, MA 02139, USA; 3Heinrich Pette Institute, Leibniz Institute for 14 Experimental Virology, 20251 Hamburg, Germany; 4Institut Pasteur, HIV, Inflammation and 15 Persistence Unit, Paris, France; 5University of Alabama at Birmingham, Birmingham, AL 35294, 16 USA 17 18 *Corresponding author 19 R. Keith Reeves 20 Center for Virology and Vaccine Research 21 Beth Israel Deaconess Medical Center 22 3 Blackfan Circle 23 Boston, MA 02215 24 Ph: (617-735-4586) 25 Fax: (617-735-4527) 26 E-mail: [email protected] 27 28 †Current address: Committee on Immunology, University of Chicago, Chicago, IL 60637, USA 29 30 Running Title: Human Memory NK Cells 31 32 Abstract: 185 words 33 Main Text: 2713 words 34 Methods Text: 2035 words 35 5 Figures 36 7 Supplemental Figures 37 3 Supplemental Tables 38 62 references 39 40 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.09.374348; this version posted November 10, 2020.
    [Show full text]